X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA FRESENIUS KABI ONCO. DISHMAN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 25.1 22.1 113.4% View Chart
P/BV x 3.3 3.1 107.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
DISHMAN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs374176 212.7%   
Low Rs12979 164.2%   
Sales per share (Unadj.) Rs197.837.7 524.9%  
Earnings per share (Unadj.) Rs21.25.1 416.4%  
Cash flow per share (Unadj.) Rs34.76.7 516.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.942.5 422.8%  
Shares outstanding (eoy) m80.69158.23 51.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.7%   
Avg P/E ratio x11.925.0 47.5%  
P/CF ratio (eoy) x7.218.9 38.3%  
Price / Book Value ratio x1.43.0 46.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30620,135 100.8%   
No. of employees `0000.81.2 72.0%   
Total wages/salary Rs m5,355703 761.5%   
Avg. sales/employee Rs Th19,252.75,176.2 371.9%   
Avg. wages/employee Rs Th6,459.5610.4 1,058.2%   
Avg. net profit/employee Rs Th2,064.1699.6 295.0%   
INCOME DATA
Net Sales Rs m15,9615,963 267.7%  
Other income Rs m26518 1,474.4%   
Total revenues Rs m16,2265,981 271.3%   
Gross profit Rs m4,1031,430 286.9%  
Depreciation Rs m1,091258 422.9%   
Interest Rs m944-26 -3,632.3%   
Profit before tax Rs m2,3341,216 191.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m624342 182.2%   
Profit after tax Rs m1,711806 212.3%  
Gross profit margin %25.724.0 107.2%  
Effective tax rate %26.728.1 95.0%   
Net profit margin %10.713.5 79.3%  
BALANCE SHEET DATA
Current assets Rs m11,0185,102 216.0%   
Current liabilities Rs m9,5172,385 399.0%   
Net working cap to sales %9.445.6 20.6%  
Current ratio x1.22.1 54.1%  
Inventory Days Days110150 73.6%  
Debtors Days Days35113 30.7%  
Net fixed assets Rs m16,3045,148 316.7%   
Share capital Rs m161158 102.0%   
"Free" reserves Rs m12,9076,556 196.9%   
Net worth Rs m14,5166,732 215.6%   
Long term debt Rs m4,189952 440.0%   
Total assets Rs m29,80510,388 286.9%  
Interest coverage x3.5-45.8 -7.6%   
Debt to equity ratio x0.30.1 204.0%  
Sales to assets ratio x0.50.6 93.3%   
Return on assets %8.97.5 118.7%  
Return on equity %11.812.0 98.5%  
Return on capital %17.514.6 120.0%  
Exports to sales %24.874.5 33.3%   
Imports to sales %3.724.8 15.1%   
Exports (fob) Rs m3,9564,441 89.1%   
Imports (cif) Rs m5961,477 40.4%   
Fx inflow Rs m4,9525,298 93.5%   
Fx outflow Rs m6971,772 39.3%   
Net fx Rs m4,2553,525 120.7%   
CASH FLOW
From Operations Rs m2,7861,274 218.7%  
From Investments Rs m-1,529-1,204 127.0%  
From Financial Activity Rs m-941-196 479.9%  
Net Cashflow Rs m316-126 -250.5%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 9.6 132.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 42,599 108.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS